Measured by its binding ability in a functional ELISA. When Lokivetmab(Anti-Canine IL-31Recombinant Antibody) is immobilized 0.5µg/mL (100µL/well), Recombinant Canine IL-31 binds with an EC50 of 0.07-1ng/ml.
Lokivetmab
Lokivetmab
Price:
Regular price
$116.00 USD
Regular price
Sale price
$116.00 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Species | Canine |
| Synonyms | Cytopoint |
| Expression System | CHO |
| Molecular Weight | 25-27 kDa (Light Chain) & 53-55 kDa (Heavy Chain) (Reducing) |
| Purity | ＞95% by SDS-PAGE |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, pH7.4. |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference | 1. Matthew Krautmann. Laboratory safety evaluation of lokivetmab, a canine anti-interleukin-31 monoclonal antibody, in dogs. Vet Immunol Immunopathol. 2023 Apr:258:110574. |
Background
Lokivetmab is a caninized anti-IL-31 mAb that binds and neutralizes canine IL-31, resulting in reduced skin lesions and inhibition of pruritus in dogs with AD or allergic dermatitis. Lokivetmab is the first mAb approved for use in dogs with canine AD and allergic dermatitis by regulatory agencies worldwide. Lokivetmab targets canine IL-31 specifically and does not bind to murine or human IL-31 or to any other canine proteins. After s.c. administration, lokivetmab is absorbed and incorporated into the pool of circulating antibodies. The long terminal elimination half-life of lokivetmab in dogs of 16.5 ± 3.0 days is due to recycling via the FcRn receptor and allows for monthly injections to maintain efficacy. Elimination by catabolism is identical to any endogenous protein. Lokivetmab binds at a single epitope on canine IL-31, forming a mAb:IL-31 complex having pharmacokinetics and elimination like unbound lokivetmab.
Picture
Picture
Bioactivity
SDS-PAGE
2μg (R: reducing condition).
